OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Sep 5, 2022 • 12min
S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.
Sep 1, 2022 • 20min
S7 Ep27: Iams and Shah Break Down Lambert-Eaton Myasthenic Syndrome in SCLC and Other Neuroendocrine Cancers
Drs Iams and Shah discuss the process of diagnosing Lambert-Eaton myasthenic syndrome in neuroendocrine cancers, how the condition affects patient prognoses, and the primary goals of delivering coordinated care with in combination with cancer treatments.
Aug 29, 2022 • 25min
S7 Ep26: Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors
Drs Bekaii-Saab, George, and von Mehren discuss key efficacy data and patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating the novel ULK inhibitor DCC-3116 in patients with advanced or metastatic RAS or RAF–mutated solid tumors, and how vimiseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.
Aug 25, 2022 • 11min
S7 Ep25: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC
Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.
Aug 22, 2022 • 12min
S7 Ep24: Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer
Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.
Aug 18, 2022 • 20min
S7 Ep24: Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates
Drs Goldberg and Sussman discuss key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these differences, and ways these disparities can be addressed.
Aug 15, 2022 • 14min
S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and lingering questions left unanswered by the pivotal ARASENS study.
Aug 11, 2022 • 17min
S7 Ep22: Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.
Aug 8, 2022 • 1h 3min
S7 Ep21: Leukemia Experts Reflect on Defining Moments as Women in the Field
Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decisions, as well as how they interact with and support other female colleagues.
Aug 4, 2022 • 16min
S7 Ep20: Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes
Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing and genetics on treatment decisions, and the need for honest and comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.
